Oncotarget

Research Papers:

Accelerated BRAF mutation analysis using a fully automated PCR platform improves the management of patients with metastatic melanoma

Delphine Serre, Julia Salleron, Marie Husson, Agnès Leroux, Pauline Gilson, Jean-Louis Merlin, Lionnel Geoffrois and Alexandre Harlé _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:32232-32237. https://doi.org/10.18632/oncotarget.25957

Metrics: PDF 541 views  |   HTML 859 views  |   ?  


Abstract

Delphine Serre1, Julia Salleron2, Marie Husson3, Agnès Leroux4, Pauline Gilson4, Jean-Louis Merlin4, Lionnel Geoffrois1 and Alexandre Harlé4

1Institut de Cancérologie de Lorraine, Département d’Oncologie Médicale, Vandoeuvre-lès-Nancy Cedex 54519, France

2Institut de Cancérologie de Lorraine, Cellule Data Biostatistiques, Vandoeuvre-lès-Nancy Cedex 54519, France

3Institut de Cancérologie de Lorraine, Biopathologie, Vandoeuvre-lès-Nancy Cedex 54519, France

4Université de Lorraine, CNRS UMR 7039 CRAN, Institut de Cancérologie de Lorraine, Service de Biopathologie, Vandoeuvre-lès-Nancy Cedex 54519, France

Correspondence to:

Alexandre Harlé, email: a.harle@nancy.unicancer.fr

Keywords: metastatic melanoma; BRAF; automated real-time PCR; therapeutic management

Received: May 02, 2018     Accepted: July 31, 2018     Published: August 14, 2018

ABSTRACT

Background: Determination of BRAF status is important for the therapeutic management of patients with metastatic melanoma.

Objectives: We evaluated the impact of a faster determination of BRAF mutational status on the delay between initial consultation and initiation of treatment.

Results: For the FA-PCR group a median delay of 16 days [11;18] was observed between initial consultation and the implementation of treatment, which was significantly lower than that observed for the SOP group (26 days [20;46], p = 0.035).

Conclusions: In comparison to using conventional SOP, using an FA-PCR platform for BRAF mutation analysis of patients with metastatic melanoma significantly reduced the delay in initiation of personalized therapy by 10 days.

Materials and Methods: Analysis of the BRAF mutation status of eight formalin-fixed paraffin-embedded (FFPE) tissue samples was performed using a CE-IVD fully-automated (FA) PCR-based platform. The delay between initial consultation and the implementation of treatment was compared between these samples (FA-PCR group) and a retrospective group of 29 FFPE samples analysed by standard operating procedures (SOP group) using conventional PCR.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25957